Temple OrthoBiologics aims to address issues with scar tissue in joints, the news release said. The company’s flagship product is TX-33, which is designed for muscle recovery and repair in athletes. The product aims to prevent scar tissue from forming after an injury or surgery.
The company’s research and development hub is in Belgium and has partnerships in the U.S., Netherlands and Canada.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.